Interferon alfa

Interferon alfacon-1 (Inferax ), interferon alfa-2b (IntronA ), and interferon alfa-2a (Roferon -A) are applied in the treatment of chronic hepatitis B and C and some malignancies, especially hairy cell leukemia. IFN-a proteins induce the expression of antiviral, antiproliferative and immunomodulatory genes. [Pg.411]

Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C a randomised trial. Lancet 358 958-965... [Pg.23]

Bain VG, Kaita KD, Yoshida EM, Swain MG, Heathcote EJ, Neumann AU, FisceUa M, Yu R, Osborn BE, Cronin PW, Ereimuth WW, McHutchison JG, Subramanian GM (2006) A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patients. J Hepatol 44 671-678... [Pg.230]

BriUanti S, Garson J, FoU M, Whitby K, Deaville R, Masci C, MigUoU M, Barbara L (1994) A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C. Gastroenterology 107 812-817... [Pg.231]

Brockmeyer NH, Poflhoff A, Bader A, Hochdorfer B, Schlottmann R, Rasokat H, Altmeyer P, Kreuter A (2006) Treatment of condylomata acuminata with pegylated interferon alfa-2b in HIV-infected patients. Eur J Med Res 11 27-32... [Pg.231]

Carreno V, MarceUin P, Hadziyannis S, Salmeron J, Diago M, Kitis GE, Vafiadis I, Schalm SW, Zahm F, Manzarbeitia F, Jimenez FJ, Quiroga JA (1999) Retreatment of chrome hepatitis B e antigen-positive patients with recombinant interferon alfa-2a. Hepatology 30 277-282... [Pg.231]

Farci P, Mandas A, Coiana A, Lai ME, Desmet V, Van Eyken P, Gibo Y, Caruso L, Scaccabarozzi S, Criscuolo D et al (1994) Treatment of chronic hepatitis D with interferon alfa-2a. N Engl J Med 330 88-94... [Pg.233]

Lampertico P, Del Ninno E, Manzin A, Donato MF, Rumi MG, Lunghi G, Morabito A, Clementi M, Colombo M (1997) A randomized, controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum. Hepatology 26 1621-1625... [Pg.236]

Lau DT, Everhart J, Kleiner DE, Park Y, VergaUa J, Schmid P, Hoofnagle JH (1997) Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. Gastroenterology 113 1660-1667... [Pg.236]

McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK (1998) Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C, Hepatitis Interventional Xherapy Group. N Engl J Med 339(21) 1485-1492... [Pg.344]

Estrogens, furosemide, hydrochlorothiazide, interferon alfa-2b, isotretinoin, propofol, and protease inhibitors (e.g., indinavir, nelfinavir, ritonavir, and saquinavir)... [Pg.118]

Interferon alfa is an antiviral agent that is effective in suppressing hepatitis B viral replication. Interferon alfa-2b and pegylated interferon alfa-2a are the only interferon therapies approved for the treatment of chronic hepatitis B. [Pg.353]

The subcutaneous dose of interferon alfa-2b (Intron A) in patients who are HBsAg-positive is either 5 million units daily (better tolerated) or 10 million units three times weekly. The dose for HBsAg-negative patients is 5 to 6 million units three times weekly. The approved dose for pegylated interferon alfa-2a (Pegasys) for chronic hepatitis B is 180 meg subcutaneously once weekly. Interferon doses may need to be adjusted in patients with renal impairment. [Pg.354]

Interferon alfa-2a (Roferon A), interferon alfa-2b (Intron-A), and interferon alfacon-1 (Infergen) are approved for chronic hepatitis C. However, they are not prescribed alone because only 12% to 16% of patients achieve a sustained virologic response (SVR). Adding ribavirin, a synthetic guanosine analogue that inhibits viral polymerase, increases the SVR rate to 35% to 45%. [Pg.356]

Prior to the introduction of imatinib, the combination of interferon-alfa and low dose cytarabine was the nontransplant treatment of choice for patients in chronic phase CML. The precise mechanism of action of interferon-alfa remains unknown. The addition of cytarabine to interferon-alfa improves the response compared with interferon alone. This combination produces cytogenetic response rates of 30%, much lower than imatinib.13 One of the major drawbacks, in addition to the low response rates, is interferon s toxicity,... [Pg.1417]

Wellferon Interferon alfa-nl Glaxo Wellcome Treatment of chronic hepatitis C... [Pg.695]

Pawlotsky JM, Pellerin M, Bouvier M, Roudot-Thoraval F, Germanidis G, Bastie A et al. Genetic complexity of the hypervariable region 1 (HVR1J of hepatitis C vims (HCV) influence on the characteristics of the infection and responses to interferon alfa therapy in patients with chronic hepatitis C. J Med Virol 1998 54[4] 256—264. [Pg.80]

Interferon alfa-2a Interferon alfa-2b 18 million IU 18 million IU 209.58 218.04 Roferon-A Intron-A ... [Pg.185]

See also in sourсe #XX -- [ Pg.2 , Pg.1293 ]

See also in sourсe #XX -- [ Pg.2 , Pg.3 , Pg.631 , Pg.632 , Pg.633 , Pg.634 ]

See also in sourсe #XX -- [ Pg.2 , Pg.190 , Pg.191 , Pg.192 ]

See also in sourсe #XX -- [ Pg.324 , Pg.333 ]

See also in sourсe #XX -- [ Pg.2 , Pg.3 , Pg.355 , Pg.356 , Pg.642 ]

See also in sourсe #XX -- [ Pg.2 , Pg.429 ]

See also in sourсe #XX -- [ Pg.134 ]

See also in sourсe #XX -- [ Pg.201 ]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...